Sanofi's stock price decreased by 1.64% in after-hours trading. The decline may be attributed to the news that Morgan Stanley has adjusted its price target on Regeneron Pharmaceuticals, Inc., which has a significant collaboration agreement with Sanofi. This adjustment could have influenced investor sentiment towards Sanofi, leading to the stock's decline.
Comments
No comments yet